Title:
THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES COMPRISING PD-1 AGONIST
Document Type and Number:
WIPO Patent Application WO/2013/022091
Kind Code:
A1
Abstract:
Provided is a prophylactic, symptom-suppressing, and/or therapeutic agent for autoimmune diseases, which presents little risk of infection and mitigates the burden of administering the drugs to the patient. The prophylactic, symptom-suppressing, and/or therapeutic agent having a PD-1 agonist as an active ingredient, is characterized in that: (a) the agent is administered 1 to 10 times within one month of the first administration; (b) the total dose of the PD-1 agonist is 20μg/kg to 1250μg/kg; and (c) no administration is necessary for at least 3 months after the final administration.
Inventors:
SHIBAYAMA SHIRO (JP)
IMAI MASAMICHI (JP)
IMAI MASAMICHI (JP)
Application Number:
PCT/JP2012/070498
Publication Date:
February 14, 2013
Filing Date:
August 10, 2012
Export Citation:
Assignee:
ONO PHARMACEUTICAL CO (JP)
SHIBAYAMA SHIRO (JP)
IMAI MASAMICHI (JP)
SHIBAYAMA SHIRO (JP)
IMAI MASAMICHI (JP)
International Classes:
A61K45/00; A61K38/00; A61K39/395; A61P3/10; A61P5/48; A61P17/00; A61P17/06; A61P29/00; A61P37/06
Domestic Patent References:
| WO2003011911A1 | 2003-02-13 | |||
| WO2001014557A1 | 2001-03-01 | |||
| WO2003011911A1 | 2003-02-13 | |||
| WO2004072286A1 | 2004-08-26 | |||
| WO2006121168A1 | 2006-11-16 | |||
| WO1993019196A1 | 1993-09-30 | |||
| WO2006113665A2 | 2006-10-26 | |||
| WO2008157379A2 | 2008-12-24 | |||
| WO2002043478A2 | 2002-06-06 | |||
| WO2010089411A2 | 2010-08-12 | |||
| WO2010063011A2 | 2010-06-03 | |||
| WO2010036959A2 | 2010-04-01 | |||
| WO2010029435A1 | 2010-03-18 | |||
| WO2009114335A2 | 2009-09-17 | |||
| WO2008156712A1 | 2008-12-24 | |||
| WO2003042402A2 | 2003-05-22 | |||
| WO2004072286A1 | 2004-08-26 | |||
| WO1997044362A1 | 1997-11-27 | |||
| WO2004056875A1 | 2004-07-08 | |||
| WO2001064942A1 | 2001-09-07 | |||
| WO1995019374A1 | 1995-07-20 | |||
| WO2000063243A1 | 2000-10-26 | |||
| WO1999016873A1 | 1999-04-08 | |||
| WO2011023685A1 | 2011-03-03 | |||
| WO2003011911A1 | 2003-02-13 |
Foreign References:
| JP2010229134A | 2010-10-14 | |||
| US4474893A | 1984-10-02 | |||
| US4816567A | 1989-03-28 | |||
| US5225539A | 1993-07-06 | |||
| US5530101A | 1996-06-25 | |||
| US5585089A | 1996-12-17 | |||
| US6180370B1 | 2001-01-30 | |||
| US5545806A | 1996-08-13 | |||
| US5569825A | 1996-10-29 | |||
| US5625126A | 1997-04-29 | |||
| US5633425A | 1997-05-27 | |||
| US5939598A | 1999-08-17 | |||
| US6075181A | 2000-06-13 | |||
| US6114598A | 2000-09-05 | |||
| US6150584A | 2000-11-21 | |||
| US6162963A | 2000-12-19 | |||
| US5476996A | 1995-12-19 | |||
| US5698767A | 1997-12-16 | |||
| US5565332A | 1996-10-15 | |||
| US5733743A | 1998-03-31 | |||
| US5858657A | 1999-01-12 | |||
| US5223409A | 1993-06-29 | |||
| US5403484A | 1995-04-04 | |||
| US5571698A | 1996-11-05 | |||
| US4658019A | 1987-04-14 | |||
| US6491916B1 | 2002-12-10 |
Other References:
KASAGI,S. ET AL.: "Anti-PD-1 antibody reduces CD4+PD-1+T cells and relieves the lupus-like nephritis of NZB/W F1 mice", PROCEEDINGS OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, vol. 39, 10 November 2009 (2009-11-10), pages 160, XP055067100
OKAZAKI T. ET AL.: "PD-1 and PD-1 ligands: from discovery to clinical application", INT. IMMUNOL., vol. 19, no. 7, July 2007 (2007-07-01), pages 813 - 824, XP002466284
KEYMEULEN B. ET AL.: "Insulin needs after CD3- antibody therapy in new-onset type I diabetes", N. ENGL. J. MED., vol. 352, no. 25, 23 June 2005 (2005-06-23), pages 2598 - 2608, XP008155415
NORIO ABURU, SOSETSU: "Antigen specific treatment for the inhibition and remission of type 1 diabetes", JAPANESE JOURNAL OF CLINICAL IMMUNOLOGY, vol. 31, no. 6, December 2008 (2008-12-01), pages 432 - 439, XP055144635
J. IMMUNOL., vol. 149, no. 1, 1992, pages 120 - 126
J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553
BIOCHEMISTRY, vol. 31, no. 6, 1992, pages 1579 - 1584
PROC. NATL. ACAD. SCI., vol. 90, no. 14, 1993, pages 6444 - 6448
PROC. NATL. ACAD. SCI. USA, vol. 90, no. 14, 1993, pages 6444 - 6448
J. IMMUNOL. METH., vol. 231, 1999, pages 177 - 189
J. BIOLOGICAL CHEMISTRY, vol. 269, 1994, pages 199 - 206
CANCER RESEARCH, vol. 57, 1997, pages 4008 - 4014
SCIENCE, vol. 229, 1985, pages 81 - 83
CANCER RESEARCH, vol. 53, 1993, pages 851 - 856
PROC. NATL. ACAD. SCI. USA, vol. 97, no. 2, 2000, pages 722 - 727
EMBO J., vol. 12, no. 2, 1993, pages 725 - 34
MILSTEIN ET AL., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
IMMUNOLOGY LETTERS, vol. 83, no. 3, 2002, pages 215 - 220
NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 1556 - 1561
NATURE BIOTECHNOLOGY, vol. 22, 2004, pages 575 - 582
NATURE, vol. 430, no. 6996, 2004, pages 174 - 180
JOURNAL OF MOLECULAR BIOLOGY, vol. 383, no. 5, 2008, pages 1058 - 1068
JAPAN DIABETES SOCIETY, 1 July 2010 (2010-07-01)
MILLER ET AL., MULT SCLER, vol. 14, 2008, pages 1157 - 1174
JAPAN DIABETES SOCIETY, 2010
OHNUKI ET AL., MICROSCOPY RESEARCH AND TECHNIQUE, vol. 252, 2001, pages 731 - 739
COOPER ET AL., LABORATORY INVESTIGATION, vol. 69, no. 2, 1993, pages 238 - 249
See also references of EP 2742953A4
OKAZAKI T. ET AL.: "PD-1 and PD-1 ligands: from discovery to clinical application", INT. IMMUNOL., vol. 19, no. 7, July 2007 (2007-07-01), pages 813 - 824, XP002466284
KEYMEULEN B. ET AL.: "Insulin needs after CD3- antibody therapy in new-onset type I diabetes", N. ENGL. J. MED., vol. 352, no. 25, 23 June 2005 (2005-06-23), pages 2598 - 2608, XP008155415
NORIO ABURU, SOSETSU: "Antigen specific treatment for the inhibition and remission of type 1 diabetes", JAPANESE JOURNAL OF CLINICAL IMMUNOLOGY, vol. 31, no. 6, December 2008 (2008-12-01), pages 432 - 439, XP055144635
J. IMMUNOL., vol. 149, no. 1, 1992, pages 120 - 126
J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553
BIOCHEMISTRY, vol. 31, no. 6, 1992, pages 1579 - 1584
PROC. NATL. ACAD. SCI., vol. 90, no. 14, 1993, pages 6444 - 6448
PROC. NATL. ACAD. SCI. USA, vol. 90, no. 14, 1993, pages 6444 - 6448
J. IMMUNOL. METH., vol. 231, 1999, pages 177 - 189
J. BIOLOGICAL CHEMISTRY, vol. 269, 1994, pages 199 - 206
CANCER RESEARCH, vol. 57, 1997, pages 4008 - 4014
SCIENCE, vol. 229, 1985, pages 81 - 83
CANCER RESEARCH, vol. 53, 1993, pages 851 - 856
PROC. NATL. ACAD. SCI. USA, vol. 97, no. 2, 2000, pages 722 - 727
EMBO J., vol. 12, no. 2, 1993, pages 725 - 34
MILSTEIN ET AL., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
IMMUNOLOGY LETTERS, vol. 83, no. 3, 2002, pages 215 - 220
NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 1556 - 1561
NATURE BIOTECHNOLOGY, vol. 22, 2004, pages 575 - 582
NATURE, vol. 430, no. 6996, 2004, pages 174 - 180
JOURNAL OF MOLECULAR BIOLOGY, vol. 383, no. 5, 2008, pages 1058 - 1068
JAPAN DIABETES SOCIETY, 1 July 2010 (2010-07-01)
MILLER ET AL., MULT SCLER, vol. 14, 2008, pages 1157 - 1174
JAPAN DIABETES SOCIETY, 2010
OHNUKI ET AL., MICROSCOPY RESEARCH AND TECHNIQUE, vol. 252, 2001, pages 731 - 739
COOPER ET AL., LABORATORY INVESTIGATION, vol. 69, no. 2, 1993, pages 238 - 249
See also references of EP 2742953A4
Attorney, Agent or Firm:
SAEGUSA & PARTNERS (JP)
Patent business corporation 3 Edakuni [Hajime] patent firm (JP)
Patent business corporation 3 Edakuni [Hajime] patent firm (JP)
Download PDF:
Claims: